Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity
- Pharmaceuticals (Basel). 2024 Feb 23;17(3):291. doi: 10.3390/ph17030291.
- 1. School of Life Science & Technology, China Pharmaceutical University, Nanjing 211198, China.
- 2. Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China.
Background: Breast Cancer is a commonly diagnosed Cancer worldwide. Human MutT homolog 1 (MTH1) is found to be elevated in breast Tumors and Cancer cells need MTH1 for survival. Pharmacological inhibition of MTH1 may be potentially beneficial in the treatment of Breast Cancer.
Methods: MA-24 was screened by malachite green colorimetric assay for MTH1 inhibitors and the kinetic characteristics of MA-24 were assessed. The features of MA-24's binding with MTH1 were ascertained through molecular docking, and the cytotoxic activity of MA-24 was validated in vitro and in vivo. Target engagement assays, comet assay, and Western blot confirmed the intracellular target and mechanism of MA-24.
Results: MA-24 shows potent antitumor bioactivity both in vitro and in vivo. MA-24 competitively inhibited the MTH1 and further induced DNA strand breaks, leading to increased Apoptosis of Cancer cells depending on the upregulation of the cleaved-caspase 3-cleaved-PARP axis. In particular, MA-24 exhibited a powerful efficacy and safety in vivo (tumor growth inhibition rate: 61.8%).
Conclusions: MA-24 possesses a broad spectrum of Breast Cancer cytotoxicity and offered valuable insights for overcoming the challenges of chemotherapy-related toxicity, which holds great potential for the further development MA-24 as an anti-cancer drug.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Others